SABCS: Seagen outlines Tukysa's value alongside Roche's ADC in breast cancer. But FDA path remains unclear
5th December 2023 Uncategorised 0SABCS: Seagen outlines Tukysa’s value alongside Roche’s ADC in breast cancer. But FDA path remains unclear aliu Tue, 12/05/2023 – 15:23 More: SABCS: Seagen outlines Tukysa's value alongside Roche's ADC in breast cancer. But FDA path remains unclear Source: fierce
read more